spacer
home > ebr > summer 2018 > driving discovery
PUBLICATIONS
European Biopharmaceutical Review

Driving Discovery

EBR: What are the benefits of mass spectrometry (MS) as an analytical method?

Simon Cubbon: MS, from its early beginnings through to its current use, has seen an ever-increasing adoption; this is because of the large amounts of information, resulting in quality and, therefore, confidence that this technique can provide, ultimately, safeguarding end-users.

Additionally, both high- and low-resolution systems are becoming increasingly simpler to use; this, combined with the intricacy of products being brought to market (eg protein-based therapeutics, such as monoclonal antibodies or antibodydrug conjugates), requires techniques that can provide the necessary structural insights needed to fully characterise and understand these complexities.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Simon Cubbon works as a pharma and biopharmaceutical Vertical Marketing Manager at Thermo Fisher Scientific. He has worked within the analytical instruments industry for over 10 years, holding a variety of positions from applications scientist through to informatics product management. Simon studied for his PhD at the University of York, UK, where he was interested in using LC-MS to study the metabolic profile of long bone fractures.
spacer
Dr Simon Cubbon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Zenith Technologies win Cork Company of the Year

We’re very proud to announce that last Friday we won the Cork Company of the Year Award in the corporate category.
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement